Immunate (Human Coagulation Factor Viii, Human Von Willebrand Factor)

The factor VIII component restores the intrinsic pathway of coagulation, while von Willebrand factor promotes platelet adhesion to damaged vessels and stabilizes factor VIII in circulation. Together they re‑establish normal clot formation and reduce bleeding tendency.

The prescribed dose of Immunate is individualized by the treating physician based on the patient’s baseline factor levels, severity of the bleeding disorder, body weight, and the clinical situation (e.g., prophylaxis versus acute bleed). No fixed regimen is provided here.

Data on the use of Immunate in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the obstetric and hematology specialists.

To request Immunate, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Immunate is a plasma‑derived concentrate containing both factor VIII and von Willebrand factor, whereas many alternatives are recombinant single‑component products. The combined formulation can simplify dosing for patients who need both factors, but individual product selection depends on clinical response, inhibitor status and physician preference.

Immunate must be stored refrigerated at 2‑8 °C, protected from light, and must never be frozen or shaken. Prior to use, inspect the vial for particulate matter and follow aseptic technique when reconstituting and administering the product.

Immunate is supplied as an injectable solution for intravenous infusion. The vial is reconstituted according to the manufacturer’s instructions and administered by a qualified healthcare professional, typically over a period determined by the patient’s factor levels and clinical response.

Serious adverse events include the development of inhibitory antibodies against factor VIII, severe hypersensitivity reactions such as anaphylaxis, and thromboembolic complications. Patients should be monitored closely for signs of these reactions, especially during the first few infusions.

Immunate is contraindicated in individuals with known hypersensitivity to any of its components, including plasma‑derived proteins. It should also be avoided in patients with active, uncontrolled thrombosis or those for whom the risk of clot formation outweighs the benefit of factor replacement.